Description
Nasal Spray Format
This product is a liquid research preparation at a concentration of 1 mg/mL (10 mg total peptide in 10 mL), supplied with a metered nasal‑spray pump for research applications where intranasal administration is the study route. The intranasal route offers partial access to CNS tissue via the olfactory and trigeminal pathways, bypassing first‑pass hepatic metabolism.
Intranasal pharmacology varies substantially by molecule. Small, lipophilic peptides may achieve meaningful CNS concentrations; larger or highly hydrophilic peptides often do not. Peer‑reviewed data for intranasal PK is referenced below where available.
Parent Compound: DSIP
DSIP is an endogenous nonapeptide (WAGGDASGE) first isolated by Monnier and Schoenenberger in 1977. Modern reviews characterize it more as a stress‑modulating neuropeptide than a specific sleep inducer; human efficacy data is sparse.
Intranasal Research Context
- Published intranasal DSIP data in peer‑reviewed journals is very limited. Most clinical work used IV or SC routes.
- Schneider‑Helmert & Schoenenberger, Neuropsychobiology (1983): IV infusion in insomnia.
- Kovalzon & Strekalova, Neuroscience and Biobehavioral Reviews (2006): critical review of DSIP biology; intranasal pharmacology not specifically characterized.
Preparation Details
- Total peptide: 10 mg DSIP
- Volume: 10 mL
- Concentration: 1 mg/mL
- Format: Metered nasal‑spray pump
- Source: Solid‑phase synthesis; ≥98% HPLC, reconstituted in preservative‑containing sterile saline buffer
Known Side Effects — Intranasal Route
- Nasal irritation (common with aqueous peptide sprays)
- Rare vivid dreams, morning grogginess (class reports from parenteral studies)
- No characteristic intranasal adverse‑event pattern established
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
